2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 573

Absence Of Estrogen Receptor Alpha Reduces The Number and Function Of Bone Marrow Derived Plasmacytoid Dendritic Cells In Lupus Prone Mice
Abstract Number: 914

Accentuated Expression Of RANKL In Switched Memory B Cells From Patients With Rheumatoid Arthritis
Abstract Number: 1907

Acceptability Of Various Technology-Based Communication Modalities In a Rheumatology Clinic
Abstract Number: 2861

Accounting For Parental Load and Identification Of Multiple Risk Variants For Anti-Ro Congenital Heart Block Through High-Density Genotyping Of Immune-Related Loci
Abstract Number: 198

Accuracy Of International Classification Of Diseases (Ninth Revision) Coding For Rheumatoid Arthritis In The Primary Care Setting
Abstract Number: 825

Activating Transcription Factor 3 Regulates Canonical Transforming Growth Factor Beta Signaling In Experimental Fibrosis
Abstract Number: 823

Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages
Abstract Number: 821

Activation Of The Signal Transducer and Activator Of Transcription 3 By Transforming Growth Factor-Beta Promotes Fibroblast Activation and Tissue Fibrosis
Abstract Number: 2219

Active Immunization Against VEGF-Derived Oligopeptides Improves Joint Inflammation and Destruction In Collagen-Induced Arthritis
Abstract Number: 618

Active Renal Disease Is Associated With The Presence Of The Metabolic Syndrome (MetS) In Peruvian Patients With Systemic Lupus Erythematosus (SLE)
Abstract Number: 380

Active Rheumatoid Arthritis Is An Independent Risk Factor Of Chronic Kidney Disease
Abstract Number: 2545

Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Abstract Number: 1363

Active Tuberculosis Risk With Tumor Necrosis Factor Inhibitors After Treating Latent Tuberculosis -a 7-Year Retrospective Observational Study
Abstract Number: 2597

Acupressure For The Treatment Of Raynaud’s Phenomenon: A Pilot Randomized Controlled Trial
Abstract Number: 1674

Acute Coronary Syndromes In Patients With Giant Cell Arteritis: A Population Based Retrospective Cohort Study

« Previous Page
1
…
6
7
8
9
10
…
193
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].